Hye J. Wang

Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Effect of Ezetimibe on Glucose Metabolism and Inflammatory Markers in Adipose Tissue.

Effect of Ezetimibe on Glucose Metabolism and Inflammatory Markers in Adipose Tissue.

Journal: Biomedicines

Published: October 16, 2020

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo.

Differential Diabetogenic Effect of Pitavastatin and Rosuvastatin, in vitro and in vivo.

Journal: Journal of atherosclerosis and thrombosis

Published: September 19, 2019

Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.

Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules.

Journal: Diabetes, obesity & metabolism

Published: July 14, 2019

Reduced expression of pyruvate kinase in kidney proximal tubule cells is a potential mechanism of pravastatin altered glucose metabolism.

Reduced expression of pyruvate kinase in kidney proximal tubule cells is a potential mechanism of pravastatin altered glucose metabolism.

Journal: Scientific reports

Published: March 29, 2018

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.

Ezetimibe ameliorates steatohepatitis via AMP activated protein kinase-TFEB-mediated activation of autophagy and NLRP3 inflammasome inhibition.

Journal: Autophagy

Published: September 22, 2017

Corrigendum to "Variants of the adiponectin gene and diabetic microvascular complications in patients with type 2 diabetes" [Metab. Clin. Exp. 62 (2013) 677-685].

Corrigendum to "Variants of the adiponectin gene and diabetic microvascular complications in patients with type 2 diabetes" [Metab. Clin. Exp. 62 (2013) 677-685].

Journal: Metabolism: clinical and experimental

Published: December 04, 2016

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.

Journal: Medicine

Published: November 19, 2016

Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia.

Effects of Omega-3 Fatty Acid Supplementation on Diabetic Nephropathy Progression in Patients with Diabetes and Hypertriglyceridemia.

Journal: PloS one

Published: November 02, 2015

Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.

Chronic HMGCR/HMG-CoA reductase inhibitor treatment contributes to dysglycemia by upregulating hepatic gluconeogenesis through autophagy induction.

Journal: Autophagy

Published: September 22, 2015

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.

Journal: Endocrinology and metabolism (Seoul, Korea)

Published: September 03, 2015

Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes.

Visceral adiposity is associated with altered myocardial glucose uptake measured by (18)FDG-PET in 346 subjects with normal glucose tolerance, prediabetes, and type 2 diabetes.

Journal: Cardiovascular diabetology

Published: August 10, 2015

Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.

Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.

Journal: Metabolism: clinical and experimental

Published: May 04, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026